Big Pharma firms touted growth in China; Genentech sues ex-staffers and biosim company; Janssen licenses Yuhan's potential Tagrisso rival.

Hikma, which has established itself as a top sterile injectables manufacturer in the U.S., is now picking up a production plant in Vietnam.

Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.

The FDA says a probable cancer-causing ingredient has been found in yet another blood pressure treatment in the U.S.

Takeda is eager to close its Shire deal and take the specialty pharma under its wing, but for now it's highlighting a few strengths in its own business.

India's Glenmark is opening a $100 million plant in North Carolina to make generic drugs.

Amid reports that it will sell Shire's Xiidra and Natpara, Takeda said it may sell SHP647, a phase 3 bowel drug that would overlap its own Entyvio.

Biogen and Eisai defend Alzheimer's drug; Taiho and Servier's Lonsurf shows positive gastric cancer data; J&J pays $2.1 billion for Japan's…